Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers. | Third ...

A diagnosis of acquired von Willebrand disease and stage 2 multiple myeloma followed unusual symptoms, leading to extensive testing. Treatment included a four-drug chemotherapy regimen and an ...

Once thought to be a flaw in the system, new research suggests that CD4 T cells may actually hold the key to maintaining a ...

Chimeric antigen receptor (CAR) T cell therapy, which uses a patient's own immune cells to fight cancer, has emerged as a powerful way to treat lymphoma and other blood cancers. But researchers have ...